Here's what to expect this week on Diagnostic Imaging.
In this week’s preview, here are some highlights of what you can expect to see coming soon:
COVID-19 vaccine-related adenopathies picked up on breast imaging have garnered a great deal of attention over the past few months. In a new study published in Clinical Imaging, investigators discuss patterns identified on scans that can give providers confidence in rendering a benign assessment. Look for the article later this week.
For more COVID-19 vaccine-related adenopathies and breast imaging coverage, click here.
The use of contrast-enhanced mammography is growing, but does it work the same across all pieces of equipment? In a new study published this week, researchers point out that artifacts picked up via this type of scan show up differently on equipment produced by different vendors. Watch for the article this week.
For more contrast-enhanced mammography coverage, click here.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Have you ever wondered if there is a way to choose the best radiology resident for your program? It turns out there are factors you should consider that will help you select the best candidates who will likely to on to have the most success. Look for an article this week that outlines what those characteristics might be.
For more coverage of radiology residency, click here.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.